- Home
- VRNA vs ROIV Comparison
VRNA vs ROIV Comparison
Compare VRNA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- ROIV
- Stock Information
- Founded
- VRNA 2005
- ROIV 2014
- Country
- VRNA United Kingdom
- ROIV United Kingdom
- Employees
- VRNA N/A
- ROIV N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- VRNA Health Care
- ROIV Health Care
- Exchange
- VRNA Nasdaq
- ROIV Nasdaq
- Market Cap
- VRNA 8.3B
- ROIV 8.6B
- IPO Year
- VRNA 2017
- ROIV N/A
- Fundamental
- Price
- VRNA $106.91
- ROIV $16.14
- Analyst Decision
- VRNA Buy
- ROIV Strong Buy
- Analyst Count
- VRNA 11
- ROIV 8
- Target Price
- VRNA $114.10
- ROIV $19.94
- AVG Volume (30 Days)
- VRNA 1.5M
- ROIV 9.5M
- Earning Date
- VRNA 11-03-2025
- ROIV 11-11-2025
- Dividend Yield
- VRNA N/A
- ROIV N/A
- EPS Growth
- VRNA N/A
- ROIV N/A
- EPS
- VRNA N/A
- ROIV N/A
- Revenue
- VRNA $221,673,000.00
- ROIV $23,233,000.00
- Revenue This Year
- VRNA $909.96
- ROIV N/A
- Revenue Next Year
- VRNA $76.47
- ROIV $248.22
- P/E Ratio
- VRNA N/A
- ROIV N/A
- Revenue Growth
- VRNA N/A
- ROIV N/A
- 52 Week Low
- VRNA $31.09
- ROIV $8.73
- 52 Week High
- VRNA $106.94
- ROIV $16.79
- Technical
- Relative Strength Index (RSI)
- VRNA 72.60
- ROIV 77.88
- Support Level
- VRNA $105.78
- ROIV $14.86
- Resistance Level
- VRNA $106.86
- ROIV $16.79
- Average True Range (ATR)
- VRNA 0.16
- ROIV 0.47
- MACD
- VRNA -0.04
- ROIV 0.05
- Stochastic Oscillator
- VRNA 98.26
- ROIV 72.27
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.